Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 5, 2013, Pages 685-705

  Travis, William D ^a   Brambilla, Elisabeth ^b   Noguchi, Masayuki ^c   Nicholson, Andrew G ^d   Geisinger, Kim ^e   Yatabe, Yasushi ^f   Ishikawa, Yuichi ^g   Wistuba, Ignacio ^h   Flieder, Douglas B ⁱ   Franklin, Wilbur ^j   Gazdar, Adi ^k   Hasleton, Philip S ^l   Henderson, Douglas W ^m   Kerr, Keith M ⁿ   Nakatani, Yukio ^o,p   Petersen, Iver ^q   Roggli, Victor ^r   Thunnissen, Erik ^s   Tsao, Ming ^t  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g CANCER INSTITUTE   (Japan)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l WYTHENSHAWE HOSPITAL   (United Kingdom)

^m FLINDERS MEDICAL CENTRE   (Australia)

ⁿ UNIVERSITY OF ABERDEEN   (United Kingdom)

^o CHIBA UNIVERSITY   (Japan)

^p CHIBA UNIVERSITY HOSPITAL   (Japan)

^q JENA UNIVERSITY HOSPITAL   (Germany)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^t PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; CLASSIFICATION; HUMAN; LUNG; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; PATHOLOGY; REVIEW;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; HUMANS; LUNG; LUNG NEOPLASMS;

EID: 84877975654     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0264-RA     Document Type: Review

References (181)

1. Travis WD, Brambilla E, Noguchi M, et al. The New IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol. 2011;6(2):244-285.
2. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E; in collaboration with L.H. Sobin and pathologists from 14 countries. Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin, Germany: Springer; 1999.
3. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004. World Health Organization Classification of Tumours; vol 10.
4. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classificiation. Arch Pathol Lab Med. 2012;137(5):668-684.
5. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75(12):2844-2852.
6. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary andmicropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827.
7. Morishita Y, Fukasawa M, Takeuchi M, et al. Small-sized adenocarcinoma of the lung: cytologic characteristics and clinical behavior. Cancer. 2001;93(2): 124-131. (Pubitemid 32322167)
8. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-664.
9. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol. 2003;27(1):101-109. (Pubitemid 36014903)
10. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002;26(3):358-364. (Pubitemid 34184460)
11. Hata A, Katakami N, Fujita S, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol. 2010;5(8): 1197-1200.
12. Sawada E, Nambu A, Motosugi U, et al. Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. Jpn J Radiol. 2010; 28(4):251-258.
13. Lee HY, Lee KS, Han J, et al. Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer. 2009;65(2):170-175.
14. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer. 2008;9(1):24-29. (Pubitemid 351251597)
15. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007;9(3):320-326. (Pubitemid 47305068)
16. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116(3):319-325. (Pubitemid 32851962)
17. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer. 2010; 68(2):185-191.
18. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-340.
19. Mok TS. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol. 2011;8(11):661-668.
20. Warth A, Muley T, Meister M, et al. Back to the roots: the novel histologic IASLC/ATS/ERS classification system of invasive pulmonary adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30(13):1438-1446.
21. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009;33(12):1752-1764.
22. Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res. 2009;15(16):5184-5190.
23. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study. J Thorac Cardiovasc Surg. 2011;143(3): 607-612.
24. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008; 336(7653):1106-1110. (Pubitemid 351731739)
25. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol. 2009; 33(3):462-469.
26. Yim J, Zhu LC, Chiriboga L, et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007; 20(2):233-241. (Pubitemid 46422178)
27. Clayton F. Bronchioloalveolar carcinomas: cell types, patterns of growth, and prognostic correlates. Cancer. 1986;57:1555-1564. (Pubitemid 16135603)
28. Daly RC, Trastek VF, Pairolero PC, et al. Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg. 1991;51:368-376.
29. Goldstein NS, Mani A, Chmielewski G, Welsh R, Pursel S. Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol. 1999;112(3):391-402. (Pubitemid 30214780)
30. Manning JT Jr, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer. 1984;54:525-534. (Pubitemid 14087883)
31. Riquet M, Foucault C, Berna P, et al. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg. 2006;81(6):1988-1995. (Pubitemid 43775587)
32. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006;24(12):1807-1813. (Pubitemid 46638977)
33. Garfield DH, Cadranel J. The importance of distinguishing mucinous and nonmucinous bronchioloalveolar carcinomas. Lung. 2009;187(3):207-208.
34. West HL, Garfield DH. Bronchioloalveolar carcinoma: not as easy as "BAC." J Thorac Oncol. 2009;4(9):1047-1048.
35. Gandara DR, Aberle D, Lau D, et al. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006;1(9 suppl):S20-S26. (Pubitemid 47181354)
36. Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer. 2006;7(5):313-322. (Pubitemid 43950978)
37. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005;23(14):3279-3287. (Pubitemid 46211352)
38. Carey FA,Wallace WA, Fergusson RJ, Kerr KM, Lamb D. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. Thorax. 1992;47:1041-1043. (Pubitemid 23011022)
39. Weng SY, Tsuchiya E, Kasuga T, Sugano H. Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchows Arch A Pathol Anat Histopathol. 1992;420(6):463-471.
40. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med. 1990;114(4):363-368. (Pubitemid 20135839)
41. Nakahara R, Yokose T, Nagai K, Nishiwaki Y, Ochiai A. Atypical adenomatous hyperplasia of the lung: a clinicopathological study of 118 cases including cases with multiple atypical adenomatous hyperplasia. Thorax. 2001; 56(4):302-305. (Pubitemid 32269811)
42. Miller RR. Bronchioloalveolar cell adenomas. Am J Surg Pathol. 1990; 14(10):904-912. (Pubitemid 20317775)
43. Nakayama H, Noguchi M, Tsuchiya R, Kodama T, Shimosato Y. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol. 1990;3(3):314-320.
44. Niho S, Yokose T, Suzuki K, et al. Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol. 1999;154(1):249-254. (Pubitemid 29031632)
45. Sakamoto H, Shimizu J, Horio Y, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol. 2007;212(3):287-294. (Pubitemid 47010062)
46. WestraWH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56(9):2224-2228. (Pubitemid 26119929)
47. Kohno T, Kakinuma R, Iwasaki M, et al. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs. Carcinogenesis. 2010;31(10):1794- 1799.
48. Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer. 2005;50(1):1-8. (Pubitemid 41297463)
49. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29(5): 633-639. (Pubitemid 40577873)
50. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma: analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol. 1996; 20(5):553-562. (Pubitemid 26129443)
51. Takamochi K, Ogura T, Suzuki K, et al. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol. 2001;159(5):1941-1948. (Pubitemid 33062536)
52. Licchesi JD, Westra WH, Hooker CM, Herman JG. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res. 2008;14(9):2570-2578.
53. Nakanishi K, Kawai T, Kumaki F, et al. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol. 2002;33(7):697-702. (Pubitemid 34953348)
54. Seki N, Takasu T, Mandai K, et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res. 2002;8(10):3046-3053. (Pubitemid 35155013)
55. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 2008;29(5):895-904. (Pubitemid 351982232)
56. Kerr KM, MacKenzie SJ, Ramasami S, et al. Expression of FHIT, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma. J Pathol. 2004;203(2):638-644. (Pubitemid 38714100)
57. Maeshima AM, Tochigi N, Yoshida A, et al. Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J Thorac Oncol. 2010;5(4): 466-471.
58. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol. 2001;14(2):72-84. (Pubitemid 32173389)
59. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol. 1999;111(5):610-622. (Pubitemid 29200948)
60. Koga T, Hashimoto S, Sugio K, et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol. 2002;117(3): 464-470. (Pubitemid 34226084)
61. Watanabe S, Watanabe T, Arai K, et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg. 2002;73(4):1071-1075. (Pubitemid 34275880)
62. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg. 2004;78(5):1728-1733. (Pubitemid 39423543)
63. Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer. 2009;64(2):148-154.
64. Yoshida J, Nagai K, Yokose T, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg. 2005;129(5):991-996. (Pubitemid 40631417)
65. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg. 2001;71(3):971-974. (Pubitemid 32210412)
66. Yamada S, Kohno T. Video-assisted thoracic surgery for pure ground-glass opacities 2 cm or less in diameter. Ann Thorac Surg. 2004;77(6):1911-1915. (Pubitemid 38686556)
67. Koike T, Togashi K, Shirato T, et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg. 2009;88(4):1106-1111.
68. Maeshima AM, Tochigi N, Yoshida A, et al. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol. 2010;5(3):333-339.
69. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133(10):1515-1538.
70. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28(2):198-206. (Pubitemid 38124728)
71. Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya R. "Early" peripheral lung cancer: prognostic significance of ground glass opacity on thinsection computed tomographic scan. Ann Thorac Surg. 2002;74(5):1635-1639. (Pubitemid 35222657)
72. Oka S, Hanagiri T, Uramoto H, et al. Surgical resection for patients with mucinous bronchioloalveolar carcinoma. Asian J Surg. 2010;33(2):89-93.
73. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-e72.
74. Lindeman N, Cagle P, Ladanyi M. CAP/IASLC/AMP lung cancer biomarkers guideline. Arch Pathol Lab Med. 2012. In press.
75. De Oliveira Duarte AR, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol. 2009;131(5):694-700.
76. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007; 98(7):1006-1013. (Pubitemid 46865384)
77. Yoshizawa A, Sumiyoshi S, Moreira AL, Travis WD. Validation of the IASLC/ATS/ERS lung adenocarcinoma (ADC) classification and use of comprehensive histologic subtyping (CHS) for architectural grading in 432 Japanese patients. Mod Pathol. 2011;24(1S):429A.
78. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34(8):1155-1162.
79. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
80. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14(8):822-827.
81. Sholl LM, Yeap BY, Iafrate AJ, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in neversmokers. Cancer Res. 2009;69(21):8341-8348.
82. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol. 2010;23(2):159-168.
83. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 2004;10(21):7311-7317. (Pubitemid 39487720)
84. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496-1504.
85. Thunnissen FB, Beasley MB, Borczuk A, et al. Reproducibility of histopathological subtypes in pulmonary adenocarcinoma. Mod Pathol. 2012; 25:e pub ahead of print.
86. Warth A, Stenzinger A, von Brunneck A-C, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS Classification. Eur Resp J. 2012. In press.
87. Kadota K, Suzuki K, D'Angelo SP, et al. Validation of the proposed IASLC/American Thoracic Society (ATS)/European Respiratory Society (ERS) international multidisciplinary classification of lung adenocarcinoma (ADC). J Thorac Oncol. 2011;6(6 suppl 2):S286.
88. Kadota K, Suzuki K, Yoshizawa A, et al. Clinicopathologic characteristics of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and lepidic predominant (LPD) adenocarcinoma of the lung (LAC): Memorial Sloan-Kettering Cancer Center Experience. J Thorac Oncol. 2011;6(6 suppl 2):S287.
89. Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med. 2011;135(10):1329-1334.
90. Sterlacci W, Savic S, Schmid T, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol. 2012;137(6): 946-956.
91. Lee HY, Han J, Lee KS, et al. Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer. 2009;66(3):379-385.
92. Lin DM, Ma Y, Zheng S, et al. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol. 2006;21(6): 627-632.
93. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29(3):179-188.
94. Okudela K, Woo T, Mitsui H, et al. Proposal of an improved histological sub-typing system for lung adenocarcinoma -significant prognostic values for stage I disease. Int J Clin Exp Pathol. 2010;3(4):348-366.
95. Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol. 1997;21(1):43-51.
96. Hoshi R, Tsuzuku M, Horai T, Ishikawa Y, Satoh Y. Micropapillary clusters in early-stage lung adenocarcinomas: a distinct cytologic sign of significantly poor prognosis. Cancer. 2004;102(2):81-86. (Pubitemid 38489964)
97. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol. 2008;21(8):992-1001.
98. Kawakami T, Nabeshima K, Hamasaki M, et al. Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch. 2009;454(1):61-70.
99. Kuroda N, Hamaguchi N, Takeuchi E, et al. Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS. 2006; 114(5):381-385. (Pubitemid 43829429)
100. Maeda R, Isowa N, Onuma H, et al. Lung adenocarcinomas with micropapillary components. Gen Thorac Cardiovasc Surg. 2009;57(10):534-539.
101. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (-/-20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology. 2005;46(6):677-684. (Pubitemid 40834827)
102. Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol. 2008;39(3):324-330. (Pubitemid 351186688)
103. Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol. 2007;20(6):638-647. (Pubitemid 46788870)
104. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol: 2012;25(3):405-415.
105. Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol. 2004;121(5):644-653. (Pubitemid 38533996)
106. Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol. 2010;5(6):830-836.
107. Copin MC, Buisine MP, Leteurtre E, et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol. 2001;32(3):274-281. (Pubitemid 32246800)
108. Miyake H, Matsumoto A, Terada A, et al. Mucin-producing tumor of the lung: CT findings. J Thorac Imaging. 1995;10(2):96-98.
109. Sato K, Ueda Y, Shikata H, Katsuda S. Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: immunohistochemical studies and mutation analysis of the p53 gene. Pathol Res Pract. 2006;202(10):751-756. (Pubitemid 44362200)
110. Gaeta M, Blandino A, Scribano E, et al. Mucinous cystadenocarcinoma of the lung: CT-pathologic correlation in three cases. J Comput Assist Tomogr. 1999; 23(4):641-643. (Pubitemid 29337164)
111. Cohen PR, Yoshizawa A, Motoi N, et al. Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic feature or a histologic subtype? Mod Pathol. 2010;23(2):400A.
112. Deshpande CG, Yoshizawa A, Motoi N, et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol. 2009;22(1S):352A.
113. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5213.
114. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005;29(5):660-665. (Pubitemid 40577877)
115. Nakatani Y, Kitamura H, Inayama Y, et al. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol. 1998;22(4):399-411. (Pubitemid 28164545)
116. Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol. 2002;15(6):617-624. (Pubitemid 34666465)
117. Nakatani Y, Miyagi Y, Takemura T, et al. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol. 2004;28(7):921-927. (Pubitemid 38856849)
118. Chu PG, Chung L, Weiss LM, Lau SK. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol. 2011;35(12):1830-1836.
119. Moran CA, Hochholzer L, Fishback N, Travis WD, Koss MN. Mucinous (so-called colloid) carcinomas of lung. Mod Pathol. 1992;5(6):634-638.
120. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004;28(4):442-452. (Pubitemid 38436517)
121. Gao ZH, Urbanski SJ. The spectrum of pulmonary mucinous cystic neoplasia: a clinicopathologic and immunohistochemical study of ten cases and review of literature. Am J Clin Pathol. 2005;124(1):62-70. (Pubitemid 40944375)
122. Geisinger KR, Levine EA, Shen P, Bradley RF. Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol. 2007;127(1):135-143. (Pubitemid 46797029)
123. Sekine S, Shibata T, Matsuno Y, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol. 2003; 200(2):214-221. (Pubitemid 36748030)
124. Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature. Am J Clin Pathol. 2009;131(1): 129-133.
125. Hatanaka K, Tsuta K, Watanabe K, Sugino K, Uekusa T. Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: a report of the second case negative for cytokeratin 7. Pathol Res Pract. 2011;207(3):188-191.
126. Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159(6):2239-2248. (Pubitemid 33104277)
127. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome, part I: the utility of immunohistochemistry. J Mol Diagn. 2008; 10(4):293-300. (Pubitemid 352019113)
128. Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol. 2005;18(6): 816-821. (Pubitemid 40780515)
129. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010;116(3):659-669.
130. Nakazato Y, Minami Y, Kobayashi H, et al. Nuclear grading of primary pulmonary adenocarcinomas: correlation between nuclear size and prognosis. Cancer. 2010;116(8):2011-2019.
131. Petersen I, Kotb WF, Friedrich KH, et al. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer. 2009;65(3):312-318.
132. Kadota K, Suzuki K, Kachala SS, et al. Mitotic count is a predictor of recurrence in stage I lung adenocarcinoma generating a combined architectural and mitotic grading system. Mod Pathol. 2012;25(8):1117-1127.
133. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1): 13-17.
134. Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer. 2010;72(3):309-315.
135. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study. J Thorac Oncol. 2011;7(2):348-354.
136. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
137. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010;29(1):23-36.
138. Hayes DF, Allred C, Anderson BO, et al. Breast. In: AJCC Cancer Staging Manual 7th Edition, Edge SB, Byrd DR, Compton CC, et al, eds. New York, NY: Springer; 2009.
139. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137(1):46-52.
140. Iwata T, Sugio K, Uramoto H, et al. Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas. Front Biosci. 2011;17: 2961-2969.
141. Chung JH, Choe G, Jheon S, et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol. 2009;4(12):1490-1495.
142. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int. 2007;57(5):233-244. (Pubitemid 46595031)
143. Holst VA, Finkelstein S, Yousem SA. Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol. 1998;22(11): 1343-1350. (Pubitemid 28499124)
144. Furak J, Trojan I, Szoke T, et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg. 2003; 23(5):818-823. (Pubitemid 36566580)
145. Akira M, Atagi S, Kawahara M, Iuchi K, Johkoh T. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. AJR Am J Roentgenol. 1999;173(6):1623-1629.
146. Tateishi U, Muller NL, Johkoh T, et al. Mucin-producing adenocarcinoma of the lung: thin-section computed tomography findings in 48 patients and their effect on prognosis. J Comput Assist Tomogr. 2005;29(3):361-368. (Pubitemid 40734600)
147. Yabuuchi H, Murayama S, Murakami J, et al. High-resolution CT characteristics of poorly differentiated adenocarcinoma of the peripheral lung: comparison with well differentiated adenocarcinoma. Radiat Med. 2000;18(6): 343-347. (Pubitemid 32049872)
148. Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 2001;220(3):803-809. (Pubitemid 32799993)
149. Kodama K, Higashiyama M, Yokouchi H, et al. Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. Ann Thorac Surg. 2002;73(2):386-392. (Pubitemid 34117375)
150. Im JG, Han MC, Yu EJ, et al. Lobar bronchioloalveolar carcinoma: "angiogram sign" on CT scans. Radiology. 1990;176(3):749-753. (Pubitemid 20266768)
151. Nagao M, Murase K, Yasuhara Y, et al. Measurement of localized groundglass attenuation on thin-section computed tomography images: correlation with the progression of bronchioloalveolar carcinoma of the lung. Invest Radiol. 2002; 37(12):692-697. (Pubitemid 35429190)
152. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu. 1988;23(pt 2):361-394.
153. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15(5):538-542. (Pubitemid 34521403)
154. Sarantopoulos GP, Gui D, Shintaku P, et al. Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation. Arch Pathol Lab Med. 2004;128(4):406-414. (Pubitemid 38451127)
155. Shah RN, Badve S, Papreddy K, et al. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol. 2002;33(9):915-920.
156. Simsir A, Wei XJ, Yee H, Moreira A, Cangiarella J. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2004;121(3):350-357. (Pubitemid 38298168)
157. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35(1):3-7. (Pubitemid 38139310)
158. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and nonmucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. Virchows Arch. 2002;440(6):598-603. (Pubitemid 34809691)
159. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol. 1996;179(3):254-259. (Pubitemid 26266402)
160. Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol. 2007;128(1):100-108. (Pubitemid 47121721)
161. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006;12(5):1647-1653.
162. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-smallcell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857-865. (Pubitemid 46224186)
163. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93(3):355-363. (Pubitemid 43080038)
164. Ohtsuka T, Watanabe K, Kaji M, Naruke T, Suemasu K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J Cardiothorac Surg. 2006;30(1):160-163. (Pubitemid 43850329)
165. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006; 24(11):1679-1688. (Pubitemid 46622139)
166. Bryant CM, Albertus DL, Kim S, et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS ONE. 2010;5(7):1-13.
167. Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res. 2006;12(3 pt 1):710-717. (Pubitemid 43259849)
168. Ohtsuka K, Ohnishi H, Furuyashiki G, et al. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol. 2006;1(8):787-795. (Pubitemid 47181383)
169. Soh J, Toyooka S, Ichihara S, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol. 2008;3(4):340-347. (Pubitemid 351489472)
170. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of BRAFV600E-mutated lung adenocarcinoma. Am J Surg Pathol. 2008;32(9):1317-1321.
171. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: significance of the micropapillary pattern and the hobnail cell type. Lung Cancer. 2009;63(2):235-240.
172. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005;23(28):6838-6845.
173. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005;65(17):7568-7572. (Pubitemid 41297226)
174. Tanaka R, Horikoshi H, Nakazato Y, et al. Magnetic resonance imaging in peripheral lung adenocarcinoma: correlation with histopathologic features. J Thorac Imaging. 2009;24(1):4-9.
175. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004;57(4):383-387. (Pubitemid 38446256)
176. Koga T, Hashimoto S, Sugio K, et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res. 2001;7(6):1730-1738. (Pubitemid 32708642)
177. Kim YT, Kim TY, Lee DS, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2008;59(1):111-118.
178. Tsuta K, Ishii G, Nitadori J, et al. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol. 2006;209(1):78-87.
179. Ang DC, Zakowski MF, Ladanyi M, Moreira AL, Rekhtman N. Characteristic morphology and immunoprofile of lung adenocarcinoma with KRAS mutations: propensity for solid growth pattern and correlation with TTF-1 expression. Mod Pathol. 2010;23(suppl 2):396A.
180. Shrestha B, Ebihara Y, Osakabe Y, Kato H. Immunohistochemical, ultrastructural and molecular study of well differentiated adenocarcinomas of the lung predominantly composed of goblet cells. Lung Cancer. 1998;22(2):103-117. (Pubitemid 29050852)
181. Yatabe Y, Koga T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203(2):645-652. (Pubitemid 38714101)